CN103446500A - Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction - Google Patents
Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction Download PDFInfo
- Publication number
- CN103446500A CN103446500A CN2013104200093A CN201310420009A CN103446500A CN 103446500 A CN103446500 A CN 103446500A CN 2013104200093 A CN2013104200093 A CN 2013104200093A CN 201310420009 A CN201310420009 A CN 201310420009A CN 103446500 A CN103446500 A CN 103446500A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- cyclomastopathy
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 235000013336 milk Nutrition 0.000 title abstract description 13
- 210000004080 milk Anatomy 0.000 title abstract description 13
- 239000008267 milk Substances 0.000 title abstract description 13
- 208000002193 Pain Diseases 0.000 title abstract description 12
- 230000036407 pain Effects 0.000 title abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 241000628997 Flos Species 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 19
- 206010006298 Breast pain Diseases 0.000 claims description 18
- 208000006662 Mastodynia Diseases 0.000 claims description 18
- 206010060710 Galactostasis Diseases 0.000 claims description 17
- -1 patch Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 210000003734 kidney Anatomy 0.000 abstract description 20
- 210000004185 liver Anatomy 0.000 abstract description 18
- 230000001105 regulatory effect Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010003549 asthenia Diseases 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 241000700159 Rattus Species 0.000 description 27
- 238000000605 extraction Methods 0.000 description 22
- 210000000481 breast Anatomy 0.000 description 20
- 210000005075 mammary gland Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 206010020718 hyperplasia Diseases 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000019395 Lactation disease Diseases 0.000 description 7
- 206010042576 Suppressed lactation Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108050006400 Cyclin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000037006 agalactosis Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003163 gonadal steroid hormone Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 241000220433 Albizia Species 0.000 description 5
- 235000011438 Albizia odoratissima Nutrition 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 208000029785 Puerperal disease Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 108010037528 lactotropin Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008971 rukuaixiao Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical group C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction. The traditional Chinese medicine composition provided by the invention has the effects of tonifying kidney, soothing the liver, regulating the chong and ren meridians, invigorating blood circulation and removing stasis and is used for treating diseases such as the kidney-asthenia and liver depression type cyclomastopathy, the mammary pain and the postpartum milk obstruction. The traditional Chinese medicine composition is mainly prepared from the following medicinal raw materials in parts by weight: 9-15 parts of cornu cervi degelatinatum, 9-15 parts of cassia twig, 9-15 parts of radix bupleuri, 8-12 parts of snakegourd fruit, 8-12 parts of angelica, 8-12 parts of ligusticum wallichii, 5-9 parts of fructus liquidambaris, 9-15 parts of raw oyster shell, 5-9 parts of flos albiziae and 5-9 parts of raw malt.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly be used for the treatment of cyclomastopathy, mastalgia and puerperal galactostasis Chinese medicine composition, relate to preparation method and the application of said composition simultaneously.
Background technology
Cyclomastopathy occupies first of the cystic hyperplasia of breast morbidity, approximately there is according to investigations 70%～80% women that cyclomastopathy is in various degree arranged, this disease is suffered from by developed country approximately 1/3 women, and data confirms that primary disease is a kind of precancerous lesion, its chance suffered from breast cancer is general female 3～5 times.Its sickness rate is ascendant trend year by year in recent years, and age of onset becomes younger gradually.
Cyclomastopathy is the modal cystic hyperplasia of breast of women, and its sickness rate accounts for the first place of mastopathy.Cyclomastopathy is mammary gland tissue conduit and lobule degeneration structurally and the growth of carrying out property connective tissue, can betide the women at postpubertal any age, common with the young women of 18～50 years old.Majority shows as breast lamellar and nodular hyperplasia enclosed mass clinically, or presents the migration distending pain, touches a tender spot, and the moon is premenstrual, and the pain increased.Development along with social modernization's process, the update of electronic product, people's cultural life also becomes and becomes increasingly abundant and anxiety, the sickness rate of mastalgia constantly raises, breast is women's vitals, hypertrophy and pain are perplexing numerous women, the physician thinks relevant with endocrine disturbance and Nervous and Mental Factors at present, but because the cause of disease of cyclomastopathy and mastalgia thereof is still not very clear, most of patients is difficult to accept the treatment of doctor trained in Western medicine analgesic, and Chinese medicine market lacks this type of medicine, this is a difficult problem urgently to be resolved hurrily.
In addition, effective treatment cyclomastopathy also early, significant for the generation of Breast Cancer Prevention clinically.For many years, western medical treatment cyclomastopathy androgens commonly used and other symptomatic treatment medicines.But there is certain side effect in the treatment of application androgen, if any some manlike performances, infringement liver etc.It is little that the Chinese traditional treatment cyclomastopathy has toxic and side effects, the advantages such as expense is low, be the Main Means of domestic current treatment primary disease, it has feasibility to aspect breast cancer development delaying, block and reverse cyclomastopathy, but existing Chinese medicine preparation curative effect is not very good.In addition, have in cyclomastopathy more than 60% and there is mastalgia, because the side effect such as infringement of doctor trained in Western medicine analgesic to gastrointestinal tract and liver, make the treatment of most of patients refusal Western medicine, and Chinese medicine market lacks the medicine that this type of can fundamentally treat mastalgia.
Hypogalactia, agalactia, galactostasis are also puerpera's commonly encountered diseases, one of frequently-occurring disease, and according to the statistics of World Health Organization, there is 47.6% puerpera's agalactia or hypogalactia in the whole world, and its popularity certainly will affect baby's growth promoter, also to suckling, causes very big difficulty.As everyone knows, breast feeding is all helpful to the mother and baby, wherein breast milk, the especially endocrine colostrum of 5d in puerperal to baby's growth promoter, to resist disease significant.Colostrum promotes the effect of lipid excretion in addition, reduces the generation of jaundice.Meanwhile, suckling also is conducive to mother's health, and sucking milk by the baby can stimulate mother's uterine contraction, reduces postpartum hemorrhage, also can reduce the morbidity of breast carcinoma and cervical cancer.Therefore, the patient of puerperal hypogalactia is treated timely and effectively, especially promote the increase of breast milk secretion in initial several days of puerperal, improve hypogalactia, agalactia, galactostasis, meet the needs that the baby feeds nursing, very important meaning is arranged.
Basic Theories of Chinese Medicine thinks that breast belongs to stomach, and nipple belongs to liver, puerperal milk very less or agalactia be called " hypogalactia ", also claim hypogalactia, because of stagnation of QI due to depression of the liver, due to milk operation is obstructed.Because of the childbirth severe loss of blood, or plain body weakness, deficiency of kidney-QI, the traditional Chinese medical science is thought the angry blood of essence and bloodization, be above milk, and lower is menses, consume impairment of QI blood puerperal, thus deficiency of vital energy insufficiency of blood, milk thereby very less or completely without, in addition puerperal easy depressed emotion, irritability stasis, hinder due to the milk operation, should the kidney invigorating soothing liver-QI, the QI invigorating nourishing the stomach, blood circulation promoting and blood stasis dispelling, dredging collateral for promoting lactation is controlled it.TCM Document is a lot of about the experience prescription of hypogalactia, agalactia, and traditional decoction, the pills etc. of adopting, prepared simply more in the past, and dosage is inaccurate, the taste discomfort, and mouthfeel is poor, swallows to carry inconvenience, is unfavorable for packed and transported and storage, easily moldy metamorphism.
But, from above-mentioned summary, can find, the treatment cyclomastopathy provided at present, mastalgia, puerperal, the Chinese traditional patent formulation of galactostasis was treated for specific typing, after needing the doctor to be diagnosed in clinical use, carry out corresponding selection and adjustment according to concrete patient's the state of an illness, thereby form specific prescription.This is desirably in pharmacy oneself with the patient and selects the expectation of medicine not conform to according to symptom.At present, the formula that also its three diseases is not all had special efficacy in Chinese traditional patent formulation.
Chinese patent literature CN1509743A discloses a stimulating milk secretion oral liquid, adopt Radix Bupleuri, Fructus Gardeniae, Pericarpium Citri Reticulatae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Fructus Hordei Germinatus, Radix Rhapontici, Fructus Liquidambaris, Squama Manis, Wang Buliu, Radix Glycyrrhizae formulated, this prescription biases toward liver-smoothing, qi-regulating, promoting blood circulation to remove obstruction in the collateral, be only applicable to the cyclomastopathy due to the stagnation of QI due to depression of the liver blood stasis.
Chinese patent literature CN1857512A disclose a kind of treat puerperal breast less, the Chinese medicine of agalactia, galactostasis, the Radix Paeoniae Alba, Semen Vaccariae, Radix Bupleuri, boiling hot river Squama Manis, Cornu Cervi Degelatinatum ten five kinds of Chinese medicine of making by the Chinese crude drug Radix Astragali, Radix Rehmanniae Preparata, Medulla Tetrapanacis, Herba Dianthi, Radix Trichosanthis, Fructus Liquidambaris, Radix Rhapontici, Radix Codonopsis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, wine parch, the appropriate amount of auxiliary materials mixed preparing forms, and it is characterized in that this medicine is hard capsule or tablet.The kidney-reinforcing drugs such as the medicine Radix Astragali of the existing the kidney invigorating of this prescription, Radix Rehmanniae Preparata, Radix Codonopsis, Cornu Cervi, also have product Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Radix Paeoniae Alba, the Radix Bupleuri of the soothing liver-QI of nourishing blood.But breast belongs to stomach, nipple belongs to liver, and how relevant with taste digestion clinical milk minimizing, obstructed is, do not solve the transporting and transforming function of the spleen and stomach problem, and QI and blood is still without the source of vital function, what takes milk? said medicine can not effectively address the above problem, and clinical efficacy is not good.
Chinese patent literature CN101716299A discloses a kind of Chinese medicine composition for the treatment of cyclomastopathy, by the crude drug of following weight, is made: Concha Ostreae 30 grams, Thallus Laminariae (Thallus Eckloniae) 15 grams, Radix Bupleuri 15 grams, the Radix Astragali 15 grams, Radix Angelicae Sinensis 15 grams, Radix Salviae Miltiorrhizae 15 grams, Radix Paeoniae Rubra 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Poria 10 grams, Semen Fructus Trichosanthis 10 grams, Rhizoma Chuanxiong 10 grams, Radix Asparagi 10 grams, Rhizoma Sparganii 10 grams, Pericarpium Citri Reticulatae Viride 10 grams, Semen Citri Reticulatae 10 grams, but above-mentioned prescription drug complexity, clinical practice shows, the party is only for particular patient, not good enough to the most of patients curative effect.
Chinese medicine has unique advantage preventing and treating the diseases such as cystic hyperplasia of breast, mastalgia, puerperal galactostasis, but because such disease pathogenesis is indefinite, on market most Chinese patent medicines take simple the kidney invigorating, send an expedition against, regulate the flow of vital energy, eliminating stagnation is as main, late result is not good enough.
Summary of the invention
In order to solve the various problems existed in prior art, the pathogenic characteristic that we sum up cyclomastopathy by Study of Etiology for " suffer from a deficiency of the kidney, Chong and Ren channel disorder is this; the stagnation of QI, expectorant are solidifying, blood stasis is mark ", established the kidney invigorating soothing liver-QI, the treatment rule of regulating qi-flowing for harmonizing stomach, hard masses softening and resolving, in conjunction with theoretical and modern pharmacological research achievement at all times, obtain Chinese medicine composition of the present invention, it melts adjusts benefit, stomach function regulating, the one that is melt into, for treatment cyclomastopathy, mastalgia, puerperal the curative effect of disease such as galactostasis remarkable.
One of purpose of the present invention, provide a kind of effective treatment cyclomastopathy, mastalgia, puerperal galactostasis and/or the method for relevant disease.
One of purpose of the present invention, provide a kind of Chinese medicine composition for the treatment of cyclomastopathy, mastalgia, puerperal galactostasis.
One of purpose of the present invention, provide a kind of method for preparing described Chinese medicine composition.
One of purpose of the present invention, provide the application of a kind of described Chinese medicine composition in the medicine for preparing cyclomastopathy, mastalgia, puerperal galactostasis.
Chinese medicine composition of the present invention is mainly made by following crude drug, based on the weight portion meter, and Cornu Cervi Degelatinatum 9-15 part, Ramulus Cinnamomi 9-15 part, Radix Bupleuri 9-15 part, Fructus Trichosanthis 8-12 part, Radix Angelicae Sinensis 8-12 part, Rhizoma Chuanxiong 8-12 part, Fructus Liquidambaris 5-9 part, Concha Ostreae 9-15 part, Flos Albiziae 5-9 part, Fructus Hordei Germinatus 5-9 part.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by following crude drug, based on the weight portion meter, Cornu Cervi Degelatinatum 10-13 part, Ramulus Cinnamomi 10-13 part, Radix Bupleuri 10-13 part, Fructus Trichosanthis 9-11 part, Radix Angelicae Sinensis 9-11 part, Rhizoma Chuanxiong 9-11 part, Fructus Liquidambaris 6-8 part, Concha Ostreae 10-14 part, Flos Albiziae 6-8 part, Fructus Hordei Germinatus 6-8 part.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by following crude drug, based on the weight portion meter, 12 parts of Cornu Cervi Degelatinatums, 12 parts of Ramulus Cinnamomi, 12 parts of Radix Bupleuri, 10 parts of Fructus Trichosanthis, 10 parts of Radix Angelicae Sinensis, 10 parts of Rhizoma Chuanxiongs, 7 parts of Fructus Liquidambaris, 12 parts of Concha Ostreae, 7 parts of Flos Albiziaes, 7 parts of Fructus Hordei Germinatus.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by following crude drug, based on the weight portion meter, and Cornu Cervi Degelatinatum 12g, Ramulus Cinnamomi 12g, Radix Bupleuri 10g, Fructus Trichosanthis 12g, Radix Angelicae Sinensis 9g, Rhizoma Chuanxiong 9g, Fructus Liquidambaris 7g, Concha Ostreae 12g, Flos Albiziae 7g, Fructus Hordei Germinatus 6g.
It is monarch drug that Cornu Cervi Degelatinatum, Ramulus Cinnamomi, Radix Bupleuri are take in the present invention, warming and recuperating the kidney-YANG, promoting the circulation of blood detumescence, liver-smoothing, qi-regulating, the kidney tonifying lactogenesis, be aided with Fructus Trichosanthis, Fructus Liquidambaris, Concha Ostreae and reduce phlegm, and hard masses softening and resolving is minister, assistant is with Radix Angelicae Sinensis, Rhizoma Chuanxiong, Flos Albiziae vital energy regualting and blood circulation-promoting, make with the Fructus Hordei Germinatus dredging collateral for promoting lactation, full side plays the kidney invigorating soothing liver-QI, the effect of regulating qi-flowing for harmonizing stomach, hard masses softening and resolving altogether, melt and adjust benefit, stomach function regulating, the one that is melt into, for cyclomastopathy, mastalgia, the puerperal disease such as galactostasis.
Monarch drug: Cornu Cervi Degelatinatum has the effect of the kidney warming sun, bone and muscle strengthening, promoting the circulation of blood detumescence.There is antiinflammatory, analgesic activity, the effect that suppresses cyclomastopathy is arranged, can suppress the growth of tumor, promote anti-tumor immune response, activate immunity mechanism, killing tumor cell, be conducive to oncotherapy.Ramulus Cinnamomi has promoting the flow of QI-blood by warming the meridian, and the effect of the positive pain of dehumidifying all has obvious anti-pain effect to mice thermic pain and acetic acid induced pain, and the analgesic effect that the Ramulus Cinnamomi alcohol extract occurs and rotundine group approach.Radix Bupleuri has soothing liver-QI for relieving depression, the effect of elevate a turnable ladder yang-energy, and modern pharmacology studies have shown that Radix Bupleuri has the effects such as antiinflammatory, analgesia, antitumor, immunomodulating.Saikoside has the antitumor cell molecule and adheres to, and disturbs tumor cell s phase DNA to synthesize and protein metabolism, suppresses cell proliferation, the effect of cell death inducing.Radix Bupleuri has immunoregulation effect.
Ministerial drug: Fructus Trichosanthis has clearing away heat and eliminating phlegm, relieving stuffiness of the chest by dispersing aggregation of pathogens, moisturizes the effect of laxation.The pharmacological research confirmation, Fructus Trichosanthis has the multiple pharmacological effect such as anti-inflammatory and antalgic, raising autoimmune ability, inhibition tumor growth.Research finds, Fructus Liquidambaris has the effect that dispelling, collateral-activating, diuretic stimulate the menstrual flow.Modern pharmacological research shows that Fructus Liquidambaris has antiinflammatory, analgesic activity, the acid of road road has certain anti-inflammatory activity for its known main effective ingredient, can obviously suppress the mice foot swelling that carrageenin causes, Dichlorodiphenyl Acetate induced mice abdominal cavity capillary permeability is hyperfunction demonstrates certain inhibitory action, and Dichlorodiphenyl Acetate causes that mice pain has certain analgesic activity.Concha Ostreae has the effect of suppressing the hyperactive liver and subsiding YANG, hard masses softening and resolving.The effect such as Concha Ostreae has enhancing immunity, antitumor, slow down aging, protect the liver.Experimentation shows the propagation that oyster active peptides can inhibition tumor cell, promotes apoptosis, and its mechanism may be with to be in harmonious proportion Cycle Arrest in apoptosis-induced gene expression relevant.
Adjuvant drug: the effect of Radix Angelicae Sinensis is invigorated blood circulation for enriching blood, menstruction regulating and pain relieving, loosening bowel to relieve constipation, there is antiinflammatory, strengthen the effects such as immunization, antitumor, inhibited to the strain of kinds of tumors tumor, can obviously suppress tumor growth, increase the macrophage number, strengthen its phagocytic function and splenocyte NK activity, obviously extend the animal survival phase.Rhizoma Chuanxiong has the effect of blood-activating and qi-promoting wind-expelling pain-stopping.There is analgesia, the effect such as anticancer.Research shows, Rhizoma Chuanxiong has direct antitumor action, the adhesive attraction of ligustrazine inhibition tumor cell and endotheliocyte simultaneously, and the effect of anticoagulation and antiplatelet aggregation, reduced the transfer of tumor.Ligustrazine has played the effect of killing off tumor cells to the regulator solution of immunocyte.Flos Albiziae has QI regulating by alleviation of mental depression, the active effect of calming the nerves, there is the activity that body is interior widely, extracorporeal suppression tumor cell is bred, its main component Quercitroside has antidepressant effect, there is the effects such as antiinflammatory, antioxidation, tranquilizing soporific, adjusting immune system, the activity that can significantly suppress monoamine oxidase A, monoamine oxidase A too much accumulates and can produce excessive amine metabolite in nervous tissue, causes the generation of all kinds of spirit depressing diseases.
Make medicine: Fructus Hordei Germinatus has the effect of circulation of qi promoting removing food stagnancy, invigorating the spleen and regulating the stomach, stimulating milk secretion relieving distension.Modern pharmacology research shows, the Ergota compounds contained in Fructus Hordei Germinatus has the effect of intending the dopamine agonist sample.Dopamine can discharge prolactin releasing factor and increase by acting on hypothalamus, suppresses the secretion of prolactin antagonist, suppresses to a certain extent the generation of cyclomastopathy.
Therefore, Chinese medicine composition of the present invention, have a kidney invigorating soothing the liver, Chong and Ren Meridians regulating, blood circulation promoting and dispersing pathogen accumulation.For suffer from a deficiency of the kidney liver energy stagnation type cyclomastopathy, mastalgia, the puerperal disease such as galactostasis.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment cyclomastopathy disease drug.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment mastalgia medicine.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment galactostasis medicine in puerperal.
One of purpose of the present invention, provide a kind of method for preparing described Chinese medicine composition, gets the traditional Chinese medicinal composition raw materials of the present invention by above-mentioned weight proportion, presses the pharmaceutics conventional method, adds conventional adjuvant, is prepared into various clinical acceptable dosage forms.
Further, described dosage form can be that peroral dosage form can be also dosage form and the exterior-applied formulation of topical, includes but not limited to a kind of in the middle of following dosage form: tablet, capsule, soft capsule, patch, gel, injection, pill, granule, suspensoid, drop pill or oral liquid etc.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention is preferably, the part or all of crude drug of solvent extraction, concentrated, remove impurity, after drying, again according to a conventional method, add conventional adjuvant, be prepared into various clinical acceptable dosage forms.Described solvent is preferably one or more of water, ethanol, acetone, chloroform, ethyl acetate, methanol.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention preferably includes following steps:
1. get above ten raw material of Chinese medicine medicines by above proportioning dosage;
2. get eight flavor Chinese herbal medicine except Cornu Cervi Degelatinatum and Concha Ostreae, soak, heating extraction 3 times, each 1-3 hour, merge the decocting liquid of three times;
3. Cornu Cervi Degelatinatum and Concha Ostreae being smashed sieves to put in extraction pot decocts separately, adds water heating extraction 0.2-2 hour, retains its medicinal liquid and medicinal residues in extraction pot;
4. by step, medicinal liquid 4. of decocting liquid 3. and step and medicinal residues mix in the lump and place in vacuum concentration pot, and room temperature to be chilled to, add ethanol, stir evenly, cold preservation hour, get supernatant, filter, filtrate recycling ethanol, be concentrated into the 45-60 ℃ of extractum of surveying relative density degree 1.25-1.28.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention preferably includes following steps:
1. get above ten raw material of Chinese medicine medicines by above proportioning dosage;
2. get eight flavor Chinese herbal medicine except Cornu Cervi Degelatinatum and Concha Ostreae, add 5-10 times of water gaging and soak, heating extraction 3 times, each 1-3 hour, merge the decocting liquid of three times;
3. Cornu Cervi Degelatinatum and Concha Ostreae being smashed sieves to put in extraction pot decocts separately, adds 5-10 and doubly measures, and heating extraction 0.2-2 hour, retain its medicinal liquid and medicinal residues in extraction pot;
4. by step, medicinal liquid 4. of decocting liquid 3. and step and medicinal residues mix in the lump and place in vacuum concentration pot, room temperature to be chilled to, adding ethanol makes to measure as 50-70% containing alcohol, stir evenly, cold preservation 10-30 hour, get supernatant, filters, filtrate recycling ethanol, be concentrated into the 45-60 ℃ of extractum of surveying relative density degree 1.25-1.28.
As one of specific embodiment of the invention scheme; get the dry extract of Chinese medicine composition of the present invention; add conventional adjuvant; preparation process or step routinely, make clinical acceptable tablet, capsule, soft capsule, injection, pill, granule, suspensoid, drop pill or oral liquid etc.
The specific embodiment
Following examples are to further illustrate of the present invention, but never limit the scope of the present invention.Further elaborate the present invention below with reference to embodiment, but it will be appreciated by those skilled in the art that the present invention is not limited to the preparation method of these embodiment and use.And those skilled in the art can be equal to replacement, combination, improvement or modify the present invention according to description of the invention, but these all will comprise within the scope of the invention.
embodiment 1
Get 9 parts of Cornu Cervi Degelatinatums, 9 parts of Ramulus Cinnamomi, 9 parts of Radix Bupleuri, 9 parts of Fructus Trichosanthis, 7 parts of Radix Angelicae Sinensis, 7 parts of Rhizoma Chuanxiongs, 7 parts of Fructus Liquidambaris, 12 parts of Concha Ostreae, 7 parts of Flos Albiziaes, 5 parts of Fructus Hordei Germinatus based on weight portion.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, and heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, add ethanol and make to be 55%, to stir evenly cold preservation 30 hours containing the alcohol amount, get supernatant, filter, filtrate recycling ethanol, be concentrated into 50 ℃ of extractum of surveying relative density degree 1.25-1.28.
Get again extractum, through conventional operation, directly or indirectly add pharmaceutically acceptable excipient to make capsule.
embodiment 2
Get 15 parts of Cornu Cervi Degelatinatums, 15 parts of Ramulus Cinnamomi, 15 parts of Radix Bupleuri, 12 parts of Fructus Trichosanthis, 12 parts of Radix Angelicae Sinensis, 12 parts of Rhizoma Chuanxiongs, 9 parts of Fructus Liquidambaris, 9 parts of Concha Ostreae, 9 parts of Flos Albiziaes, 6 parts of Fructus Hordei Germinatus based on weight portion.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, and heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, add ethanol and make to be 60%, to stir evenly cold preservation 25 hours containing the alcohol amount, get supernatant, filter, filtrate recycling ethanol, be concentrated into 50 ℃ of extractum of surveying relative density degree 1.25-1.28.
Get extractum, through conventional operation, directly or indirectly add pharmaceutically acceptable excipient to make oral liquid.
embodiment 3
Get 12 parts of Cornu Cervi Degelatinatums, 12 parts of Ramulus Cinnamomi, 12 parts of Radix Bupleuri, 10 parts of Fructus Trichosanthis, 10 parts of Radix Angelicae Sinensis, 10 parts of Rhizoma Chuanxiongs, 7 parts of Fructus Liquidambaris, 12 parts of Concha Ostreae, 7 parts of Flos Albiziaes, 7 parts of Fructus Hordei Germinatus based on weight portion.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, and heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, add ethanol and make to be 65%, to stir evenly cold preservation 25 hours containing the alcohol amount, get supernatant, filter, filtrate recycling ethanol, be concentrated into 50 ℃ of extractum of surveying relative density degree 1.25-1.28.
Get extractum, through conventional operation, directly or indirectly add the agent of pharmaceutically acceptable excipient granulation.
embodiment 4
Get 12 parts of Cornu Cervi Degelatinatums, 12 parts of Ramulus Cinnamomi, 10 parts of Radix Bupleuri, 12 parts of Fructus Trichosanthis, 9 parts of Radix Angelicae Sinensis, 9 parts of Rhizoma Chuanxiongs, 7 parts of Fructus Liquidambaris, 12 parts of Concha Ostreae, 7 parts of Flos Albiziaes, 7 parts of Fructus Hordei Germinatus based on weight portion.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve and put in extraction pot, then add eight Chinese medicines of residue, add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, room temperature to be chilled to, adding ethanol, to make containing the alcohol amount be 65%, stir evenly, cold preservation 25 hours, get supernatant, filters, filtrate recycling ethanol, be concentrated into 50 ℃ of extractum of surveying relative density degree 1.25-1.28.
embodiment 5
Get the dry extract of the Chinese medicine composition of embodiment 1 gained, add conventional adjuvant, preparation process or step, make injection routinely.
embodiment 6
Get the dry extract of the Chinese medicine composition of embodiment 2 gained, add conventional adjuvant, preparation process or step, make soft capsule routinely.
test example:
One, pharmacological evaluation basis
Test objective:
Estimate this Chinese prescription by pharmacological evaluation and there is the kidney invigorating soothing liver-QI, regulating qi-flowing for harmonizing stomach, hard masses softening and resolving effect, the dual function that integrates prevention and treat.
The preparation of zoopery medication:
Get the invention described above embodiment 3 traditional Chinese medicinal composition raw materials proportionings, add 10 times of water yields and soak 1 hour, preparation process is the same, add water make every 1ml containing the solution that is equivalent to the 3g crude drug, tested standby, for the experimental rat gastric infusion.
The foundation of animal experimental model:
Experimental animal is chosen female sd inbred rats 150～200g conventional adaptation raising 3～5 days, adopts rat to press 0.5mg/kg estradiol benzoate lumbar injection, every day 1 time, continuous 4 weeks, sets up cyclomastopathy pathology model.
The zoopery grouping:
Press kg body weight random packet, respectively organize after testing rat body weight, second pair of breast diameter there was no significant difference.Rat is equally divided into to 6 groups, 10 every group.
Blank group (N): with normal saline 0.2mL lumbar injection, every day 1 time, continuous 4 weeks, gavage distilled water 2mL/ since the 5th week only, every day 1 time, last till end in the 8th week, all the other 5 groups all by 0.5mg/kg estradiol benzoate lumbar injection, every day 1 time, modeling in continuous 4 weeks.
Model group: only start to gavage distilled water 2mL/ in after modeling the 5th week, every day 1 time;
The large small dose group of experimental drug: start to gavage experimental drug 3.6g/kg, 1.8g/kg every day 1 time in after modeling the 5th week;
Western medicine group: start to gavage tamoxifen tablet diluent 0.5mg/kg, every day 1 time in after modeling the 5th week;
Chinese medicine matched group: start to gavage RUZENGNING PIAN agent or RUKUAIXIAO PIAN dilution agent liquid 2.5g/kg in after modeling the 5th week, every day 1 time.Above gastric infusion all continues to end in the 8th week.
In experiment within the 1st week, start grouping weigh, by vernier caliper measurement rat second pair of breast diameter on average weekly 1 time;
Started to carry out in continuous 5 days rat vagina cell smear (pap staining), the ovarian function situation of test experience rat in the 4th week that tests and the 8th week.
Results of animal:
1. the impact of this Chinese prescription on hyperplasia of mammary gland model integrality and Serum Sex Hormones:
By detecting rat body weight, breast diameter, oestrous cycle and serum sex hormone level, observe the indexs such as rat mammary gland, uterus, ovary tissue variation, disclosed with this Treated with Chinese Decoction cyclomastopathy, mastalgia, puerperal galactostasis may be that integrally-regulated effect by the Endocrine hormone realizes.
Normal rats is along with the increase of the time of nursing, and breast diameter is without significant change, and model group rat modeling rear udder attachment diameter compared with normal Mus obviously increases, and along with the prolongation of time, breast diameter has no dwindles, and illustrates that the breast that animal pattern increases can not disappear voluntarily; This prescription rat breast diameter obviously dwindles (P<0.01), and approaches normal range.We take table, middle layer cells as main according to rat vaginal cell in rutting period, a small amount of bottom cell, rutting period, the rat vagina cell be take the middle and bottom layers cell as main, the characteristics of a small amount of cells of superficial layer, calculate Rats During The Estrous Cycle vaginal cell index (P+E), the ovarian function situation of test experience rat.
Experiment is by the mensuration to each group Rats During The Estrous Cycle index (P+E), and result shows: model group is than the obvious minimizing of blank group Rats During The Estrous Cycle index (P+E) (P<0.01); This prescription has clear improvement (P<0.01) to rat model P+E, and approaches normal range; Breast increases peaceful group of rat (P+E) and has no significant change.
Experiment is by the mensuration to each group hormone serum level, and result shows, the rat E after the estrogen modeling
2, the PRL level is apparently higher than normal rat, the P level obviously reduces, this prescription can make the abnormal E raise of rat model
2, PRL reduces, and reaches normal range, can make P content raise, and can block the excessive secretion of PRL in serum, suppresses the pessimal stimulation of abnormal hormone to mammary gland tissue.
Experiment shows, a large amount of exogenous hormoneses can cause the diacrisis of rat model serum hormone, and the present composition has the effect of regulating serum E2, the hormonal readiness disorders such as P, PRL.Thereby the abnormal secretion that the mechanism of action of pointing out this prescription may be the function by regulating laboratory animal hypothalamic-pituitary-ovarian gonad axis improves Serum Sex Hormones realizes, this is one of mechanism of action of this Treated with Chinese Decoction cyclomastopathy.
By detecting rat body weight, breast diameter, oestrous cycle (in Table 1-3), having disclosed, to take prescription therapeutic cyclomastopathy that the soothing the liver eliminating stagnation method of the kidney invigorating is principle may be that integrally-regulated effect by the Endocrine hormone realizes.
Table 1 is respectively organized the cyclomastopathy rat body weight and is changed
Annotate: ratio before and after the treatment of this group,
*p<0.05,
*p<0.01.
Table 2 is respectively organized cyclomastopathy rat breast diameter and is changed
Annotate: ratio before and after the treatment of this group, * P<0.05, * * P<0.01.
Table 3 is respectively organized cyclomastopathy Rats During The Estrous Cycle index (P+E) and is changed
Annotate: ratio before and after the treatment of this group, * P<0.05, * * P<0.01.
2. this Chinese prescription is on the Ultrastructural impact of hyperplasia of mammary gland model mammary gland
By Electronic Speculum and immunohistochemical analysis, this Chinese drug-treated group can make mammary gland prostate lumens areas, interstitial area and nuclear area obviously descend; And can improve endometrium mucosa projection, Interstitial cell reduces, the nucleus division reduces mutually; Make folliculus ovarii film wrinkle wall mamillary decreased number, result shows that this Chinese prescription has therapeutical effect (in Table 4) to cyclomastopathy and endometrial hyperplasia.
Table 4 is respectively organized the graphical analysis of mammary gland pathological form relatively
Annotate: with normal group ratio, △ P<0.05, △ △ P<0.01; With model group ratio, * P<0.05, * * P<0.01.
3. the impact of this Chinese prescription on hyperplasia of mammary gland model neurotransmitter and gonadal hormone
By the content of neurotransmitter (dopamine, 5-hydroxy tryptamine) and Serum Sex Hormones in detection rat gonad target organ-mammary gland tissue, serum, find rat model estradiol (E
2), lactotropin (PRL), 5-hydroxy tryptamine obviously raise, P (progesterone), dopamine obviously reduce, this Chinese drug-treated group can make the abnormal E raise of rat model
2, PRL reduces, and reaches normal range, and P content is obviously raise; Neurotransmitter in mammary gland tissue is also had to certain regulating action, in the rising dopamine, reduce the content of 5-hydroxy tryptamine, blocked the excessive secretion of PRL in serum, suppressed the stimulation of abnormal hormone to mammary gland tissue.Thereby the mechanism of action of pointing out this Chinese prescription may be the neuroendocrine function by regulating the hypothalamic-pituitary-ovarian gonad axis to be improved the abnormal secretion of some neurotransmitter and Serum Sex Hormones in mammary gland tissue and realize, this may be one of mechanism of action of this Treated with Chinese Decoction cyclomastopathy (in Table 5).
Table 5 mammary gland tissue, serum dopamine, 5-hydroxy tryptamine and Serum PRL change
Annotate: compare * P<0.05, * * P<0.01 with matched group; Compare △ P<0.01 with model group.
4. the impact of this Chinese prescription on hyperplasia of mammary gland model proliferating cell nuclear antigen and hormone receptor
Positive expression by proliferating cell nuclear antigen (PCNA) and estrogen receptor (ER), progesterone receptor (PR) in light microscopic and immunohistochemical staining discovery hyperplasia of mammary gland model animal's mammary gland tissue obviously strengthens, and this Chinese drug-treated group can make ER, PR, PCNA positive staining intensity index be down to normal range (in Table 6).
Table 6 is respectively organized ER, PR, PCNA staining power index relatively
Annotate: compare △ P<0.01 with normal group, with model group, compare * P<0.01
This test disclosed take " the soothing the liver eliminating stagnation of the kidney invigorating " can regulate hormone serum level as the Chinese traditional compound medicine of method for the treatment of, reduce mammary gland tissue to sensitivity female, progestogen, stop the overexpression of proliferating cell nuclear antigen, suppress further developing of cyclomastopathy, can play the dual function for the treatment of and prevention, for theoretical basis has been established in the canceration of Chinese medicine preventing mammary gland hyperplasia.
Beneficial effect of the present invention
1. create cyclomastopathy " the soothing the liver eliminating stagnation of the kidney invigorating " method
Investigation finds, in Patients of Mammary Gland Hyperplasia, menophania early, menopause evening, not fertility, not suckling, artificial abortion, the higher fatty acid factor proportion of happiness be high.80% above patient is because of the psychentonia aggravation.Think that the generation of primary disease is relevant with factors such as feelings will, diet, environment, heredity, relevant diseases,, Liver and kidney thin and weak with the menses of Chinese medicine loses supports, and the liver failing to maintain the normal flow of QI matches.The variation of disease is according to the rule evolution of the solidifying blood stasis of the stagnation of QI one expectorant.The overall process of suffering from a deficiency of the kidney and developing through the course of disease.Sum up this sick pathogenic characteristic with the stagnation of liver-QI kidney asthenia as the principal aspect, the stagnation of QI, expectorant coagulate, blood stasis is mark, have founded the treatment rule of " the soothing the liver eliminating stagnation of the kidney invigorating ".
2. improve the research that objectifies of cyclomastopathy syndrome
The performance of the B ultrasonic of Patients of Mammary Gland Hyperplasia and menstruation follicular phase, luteal phase, the onset of ovulation, the estrogen and progestogen level of premenstrua and the dependency of tcm syndrome are inquired into, find that these indexs and syndrome have certain dependency, sum up cyclomastopathy with kidney asthenia as the principal aspect, can have again that the stagnation of QI, expectorant are solidifying, blood stasis three types concurrently, respectively lobulus simplex Accretive Type, capsule cyclomastopathy type, the gland type cyclomastopathy type of corresponding B ultrasonic typing; It is closely related with the differentiation of symptoms and signs for classification of syndrome of cyclomastopathy that menstrual cycle is female, progesterone level changes, for the research that objectifies of the tcm syndrome of cyclomastopathy provides foundation.
3. set up cyclomastopathy Quantitative Diagnosis of TCM Syndrome standard and therapeutic evaluation system
Utilize the design of system, set up corresponding Quantitative Diagnosis of TCM Syndrome standard, cyclomastopathy Quantitative Diagnosis of TCM Syndrome table, cyclomastopathy case history observation table and objective scale point system have been drafted, completed the transformation of Chinese traditional medical diagnose data by grade distinguishing vectorization standard, perfect corresponding syndrome quantized diagnosis standard and therapeutic evaluation system; According to the Changing Pattern of Serum Sex Hormones and symptom integral value relatively, for the local sign of passing judgment on cyclomastopathy and the improvement of General Symptoms, for the science demonstration of Chinese medicine primary disease provides thinking.
Claims (5)
1. treat cyclomastopathy, mastalgia, puerperal galactostasis and/or the Chinese medicine composition of relevant disease for one kind, it is characterized in that mainly being made by following crude drug, based on the weight portion meter, Cornu Cervi Degelatinatum 9-15 part, Ramulus Cinnamomi 9-15 part, Radix Bupleuri 9-15 part, Fructus Trichosanthis 8-12 part, Radix Angelicae Sinensis 8-12 part, Rhizoma Chuanxiong 8-12 part, Fructus Liquidambaris 5-9 part, Concha Ostreae 9-15 part, Flos Albiziae 5-9 part, Fructus Hordei Germinatus 5-9 part.
2. Chinese medicine composition according to claim 1, is characterized in that mainly by following crude drug, being made, based on the weight portion meter, Cornu Cervi Degelatinatum 10-13 part, Ramulus Cinnamomi 10-13 part, Radix Bupleuri 10-13 part, Fructus Trichosanthis 9-11 part, Radix Angelicae Sinensis 9-11 part, Rhizoma Chuanxiong 9-11 part, Fructus Liquidambaris 6-8 part, Concha Ostreae 10-14 part, Flos Albiziae 6-8 part, Fructus Hordei Germinatus 6-8 part.
3. the preparation method of a Chinese medicine composition according to claim 1, is characterized in that getting the crude drug by above-mentioned weight proportion, presses the pharmaceutics conventional method, adds conventional adjuvant, is prepared into various clinical acceptable dosage forms.
4. preparation method according to claim 3, it is characterized in that described dosage form can be that peroral dosage form can be also dosage form and the exterior-applied formulation of topical, include but not limited to a kind of in the middle of following dosage form: tablet, capsule, soft capsule, patch, gel, injection, pill, granule, suspensoid, drop pill or oral liquid etc.
5. the application of Chinese medicine composition in the medicine for preparing cyclomastopathy, mastalgia, puerperal galactostasis according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310420009.3A CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310420009.3A CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446500A true CN103446500A (en) | 2013-12-18 |
| CN103446500B CN103446500B (en) | 2015-03-11 |
Family
ID=49729612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310420009.3A Expired - Fee Related CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446500B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148126A (en) * | 2015-09-22 | 2015-12-16 | 广州奇绩医药科技有限公司 | Health care food with mammary gland hyperplasia pain relieving function |
| CN105194394A (en) * | 2015-10-13 | 2015-12-30 | 臧海阳 | Traditional Chinese medicine composition for treating breast nodules caused by kidney deficiency and stagnation of liver qi |
| CN105381122A (en) * | 2015-11-30 | 2016-03-09 | 潘素荣 | Hard lump-resolving preparation for treating hyperplasia of mammary glands and preparation method for hard lump-resolving preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772142A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating liver energy stagnation and phlegm accumulation type mastoproliferation and its prepn |
| CN1958006A (en) * | 2006-11-15 | 2007-05-09 | 王信锁 | Preparation of Chinese traditional medicine for healthy chest and plumpy breasts |
| CN101011491A (en) * | 2007-01-24 | 2007-08-08 | 辽宁好护士药业（集团）有限责任公司 | Granule for expelling obstruction of galactophore and its preparation method |
| CN101716299A (en) * | 2009-11-16 | 2010-06-02 | 崔静 | Traditional Chinese medicine composition for treating hyperplasia of mammary glands |
-
2013
- 2013-09-16 CN CN201310420009.3A patent/CN103446500B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772142A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating liver energy stagnation and phlegm accumulation type mastoproliferation and its prepn |
| CN1958006A (en) * | 2006-11-15 | 2007-05-09 | 王信锁 | Preparation of Chinese traditional medicine for healthy chest and plumpy breasts |
| CN101011491A (en) * | 2007-01-24 | 2007-08-08 | 辽宁好护士药业（集团）有限责任公司 | Granule for expelling obstruction of galactophore and its preparation method |
| CN101716299A (en) * | 2009-11-16 | 2010-06-02 | 崔静 | Traditional Chinese medicine composition for treating hyperplasia of mammary glands |
Non-Patent Citations (1)
| Title |
|---|
| 乔迪: "乳络通汤剂配合按摩治疗急性乳腺炎的疗效观察，", 《中国中西医结合急救杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148126A (en) * | 2015-09-22 | 2015-12-16 | 广州奇绩医药科技有限公司 | Health care food with mammary gland hyperplasia pain relieving function |
| CN105148126B (en) * | 2015-09-22 | 2018-11-27 | 广州奇绩医药科技有限公司 | A kind of health food with improvement proliferation of mammary gland pain function |
| CN105194394A (en) * | 2015-10-13 | 2015-12-30 | 臧海阳 | Traditional Chinese medicine composition for treating breast nodules caused by kidney deficiency and stagnation of liver qi |
| CN105381122A (en) * | 2015-11-30 | 2016-03-09 | 潘素荣 | Hard lump-resolving preparation for treating hyperplasia of mammary glands and preparation method for hard lump-resolving preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446500B (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104840904A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN104162094A (en) | Traditional Chinese medicine composition for treating obese polycystic ovary syndrome, and medicinal preparation thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
| CN105412787A (en) | Medicine for treating postpartum irregular menstruation | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN107802733B (en) | Kidney-tonifying and fetus-cultivating traditional Chinese medicine composition and application thereof | |
| CN1785292A (en) | Medicine for treating flooding and spotting and its preparation method | |
| CN103071105B (en) | External traditional Chinese medicinal preparation for treating threatened abortion and preparation method thereof | |
| CN101569738A (en) | Plaster for treating mastitis, hyperplasia of mammary glands, breast lumps, join thydrops, traumatic injury, preparation method and application thereof | |
| CN104173858A (en) | Danefukang granules and preparation method thereof | |
| CN105797046A (en) | Traditional Chinese medicine composition for uterine fibroid treatment and postoperative nursing | |
| CN102861148A (en) | Chinese medicine preparation for treating primary dysmenorrheal and preparation method and application | |
| CN105943758B (en) | A kind of Chinese medicine composition that treating infertility and its application | |
| CN105535698A (en) | Traditional Chinese medicine composition for treating hyperprolactinemia and preparation method thereof | |
| CN105944020B (en) | Traditional Chinese medicine for treating ovarian function decline | |
| CN101979082B (en) | Medicament for treating cyclomastopathy and preparation method and application thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN103585573A (en) | Oral medicine for treating hysteromyoma | |
| CN103751650B (en) | One treats paracmastic Chinese medicine composition of gout and preparation method thereof | |
| CN103212030B (en) | Traditional Chinese medicine for treating liver depression type hyperplasia of mammary glands and preparation method thereof | |
| CN102198251B (en) | Chinese medicinal composition for treating climacteric syndrome and preparation method thereof | |
| CN110237161A (en) | Drug and its preparation method and application for treating menopausal syndrome | |
| CN103520329A (en) | Traditional Chinese medicine prescription used for treating prostatic cancer | |
| CN102861185A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Ma Jinge Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150311 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |